Bone disease in primary hyperparathyroidism;Doença óssea no hiperparatiroidismo primário

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 5, 2014, Pages 553-561

  Bandeira, Francisco ^a   Cusano, Natalie E ^b   Silva, Barbara C ^c   Cassibba, Sara ^d   Almeida, Clarissa Beatriz ^a   Machado, Vanessa Caroline Costa ^a   Bilezikian, John P ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Hyperparathyroidism; Nephrocalcinosis; Osteitis fibrosa cystica

Indexed keywords

25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ANALOGS AND DERIVATIVES; BLOOD; BONE DENSITY; BONE DISEASE; COMPLICATION; ECHOGRAPHY; FEMALE; FRACTURES, BONE; HUMAN; KIDNEY; MALE; OSTEITIS FIBROSA CYSTICA; PARATHYROIDECTOMY; PATHOLOGY; PRIMARY HYPERPARATHYROIDISM; RADIOGRAPHY; SKULL;

BIOMARKERS; BONE DENSITY; BONE DISEASES; CALCIUM; FEMALE; FRACTURES, BONE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; KIDNEY; MALE; OSTEITIS FIBROSA CYSTICA; PARATHYROID HORMONE; PARATHYROIDECTOMY; SKULL; VITAMIN D;

EID: 84906670542     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003381     Document Type: Review

References (55)

1. Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metabol. 2006;50(4):657-663.
2. Kulak CA, Bandeira C, Voss D, Sobieszczyk SM, Silverberg SJ, Bandeira F, et al. Marked improvement in bone mass after para-thyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab 1998;83(3):732-735.
3. Silverberg SJ, Clarke B, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocri-nol Metabol. 2014; [In press].
4. Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98(2):721-728.
5. Oliveira UE, Ohe MN, Santos RO, Cervantes O, Abrahão M, Lazaretti-Castro M, et al. Analysis of the diagnostic presentation profle, parathyroidectomy indication and bone mineral density follow-up of Brazilian patients with primary hyperparathyroid-ism. Braz J Med Biol Res. 2007;40(4):519-526.
6. Eufrazino C, Veras A, Bandeira F. Epidemiology of primary hyper-parathyroidism and its non-classical manifestations in the city of Recife, Brazil. Clin Med Insights Endocrinol Diabetes. 2013;6:69-74.
7. França TC, Griz L, Pinho J, Diniz ET, Andrade LD, Lucena CS, et al. Bisphosphonates can reduce bone hunger after parathyroidec-tomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011;51(2):131-137.
8. Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, et al. Diagnosis and management of primary hyper-parathyroidism--a scientifc statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013;57(6):406-424.
9. Bandeira FA, Oliveira RI, Griz LH, Caldas G, Bandeira C. Differences in accuracy of 99mTc-sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol. 2008;36(1):30-35.
10. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 2014; [In press].
11. Udelsman R, Akerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014; [In press].
12. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Increased bone mineral density after parathyroidec-tomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(3):729-734.
13. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462-3470.
14. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84(4):654-660.
15. Witteveen JE, Van Thiel S, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45-R53.
16. Bandeira F, Amaral L, Aragão P. Primary hyperparathyroidism. In: Bandeira F, Gharib H, Golbert A, Griz L, Faria M, eds. Endocrinology and diabetes: a problem-oriented approach. New York: Springer; 2013. p. 279-91.
17. Graal MB, Wolffenbuttel BH. Consequences of long-term hyper-parathyroidism. Neth J Med. 1998;53(1):37-42.
18. Boyle IT, Fogelman I, Boyce B, Thomson JE, Beastall GH, McIn-tosh WB, et al. 1alpha-hydroxyvitamin D3 in primary hyperpara-thyroidism. Clin Endocrinol (Oxf). 1977;7Suppl:215s-222s.
19. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341(17):1249-1255.
20. Silverberg SJ, Shane E, De La Cruz L, Dempster DW, Feldman F, Seldin D, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4(3):283-291.
21. Parisien M, Silverberg SJ, Shane E, De La Cruz L, Lindsay R, Bilezikian JP, et al. The histomorphometry of bone in primary hy-perparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 1990;70(4):930-938.
22. Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41(1):19-24.
23. Khosla S, Melton LJ, III, Wermers RA, Crowson CS, O'Fallon WM, Riggs BL. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700-1707.
24. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Bli-chert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598-602.
25. Vestergaard P, Mosekilde L. Fractures in patients with primary hy-perparathyroidism: nationwide follow-up study of 1201 patients. World J Surg. 2003;27(3):343-349.
26. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(7):2306-2312.
27. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, et al. Increased mortality and morbidity in mild primary hyper-parathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73(1):30-34.
28. Hansen S, Beck Jensen JE, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperpara-thyroidism: a case-control study using HR-pQCT. J Bone Miner Res. 2010;25(9):1941-1947.
29. Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029-1040.
30. Vu TD, Wang XF, Wang Q, Cusano NE, Irani D, Silva BC, et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone. 2013;55(1):57-63.
31. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518-530.
32. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Den-sitom. 2011;14(3):302-312.
33. Roux JP, Wegrzyn J, Boutroy S, Bouxsein ML, Hans D, Chapurlat R. The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study. Osteoporos Int. 2013;24(9):2455-2460.
34. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26(11):2762-2769.
35. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int. 2013;24(1):77-85.
36. Briot K, Paternotte S, Kolta S, Eastell R, Reid DM, Felsenberg D, et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. Bone. 2013;57(1):232-236.
37. Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, et al. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res. 2014;29(2):399-407.
38. Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, et al. Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathy-roidism. J Clin Endocrinol Metab. 2013;98(5):1963-1970.
39. Romagnoli E, Cipriani C, Nofroni I, Castro C, Angelozzi M, Scarpi-ello A, et al. "Trabecular Bone Score" (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone. 2013;53(1):154-159.
40. Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, Zhukouskaya VV, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155-162.
41. Rao DS, Wilson RJ, Kleerekoper M, Parftt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for bipha-sic disease course. J Clin Endocrinol Metab. 1988;67(6):1294-1298.
42. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocri-nol Metab. 2004;89(11):5415-5422.
43. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidec-tomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92(5):1687-1692.
44. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hy-perparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92(8):3114-3121.
45. Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K. Para-thyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res. 2012;27(5):1150-1158.
46. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88(10):4641-4648.
47. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathy-roidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 2003;88(11):5348-5352.
48. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperpara-thyroidism. Arq Bras Endocrinol Metabol. 2010;54(2):106-109.
49. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-3005.
50. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroid-ism. Am J Med. 2004;117(11):861-863.
51. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Nor-mocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.
52. Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F. Investigation of insulin resistance in patients with normocalce-mic primary hyperparathyroidism. Endocrine. 2012;42(2):419-422.
53. Wade TJ, Yen TW, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012;36(4):761-766.
54. Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gal-limard E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hy-perparathyroidism. J Clin Endocrinol Metab. 2013;98(8):3213-3220.
55. Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmeno-pausal women. J Clin Endocrinol Metab. 2006;91(5):1748-1753.